Search

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

25.47 -0.66

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

24.58

Max

25.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

191K

-51M

Pardavimai

6.7M

106M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-47.808

Darbuotojai

1,784

EBITDA

-2.1M

-46M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+27.34% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

826M

2.9B

Ankstesnė atidarymo kaina

26.13

Ankstesnė uždarymo kaina

25.47

Naujienos nuotaikos

By Acuity

50%

50%

156 / 340 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-18 23:56; UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

2026-08-18 23:56; UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

2026-08-18 23:52; UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

2026-08-18 23:51; UTC

News
Social Media
Event

La-Z-Boy Inc reported a net loss of $2.29 million and lowered its revenue guidance, leading shares to trade lower in after-market hours.

2026-08-18 23:51; UTC

News

JBS N.V. has proposed to acquire an 18% stake in Pilgrim's Pride, offering 2.086 shares per Pilgrim's Pride share. Shares are higher in after-market trading.

2026-08-18 23:46; UTC

News

Blue Owl Capital shares are lower in after-market hours following a recent bond issuance of $400 million by its affiliate. Analysts estimate fair value at $12.38.

2026-08-18 23:41; UTC

News
Social Media

UGI Corp shares rose in after-market trading on news of KKR's unsolicited $9 billion acquisition proposal, valuing the company at about $42.50 per share.

2026-08-18 23:41; UTC

News

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

2026-08-18 23:36; UTC

News

BMO Capital initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $318. Shares are higher in after-market trading.

2026-08-18 23:36; UTC

News
Correlated Moves

SPDR Gold Shares trade lower in after-market hours as Indonesia holds rates steady, while rising crude oil prices may affect inflation and market dynamics.

2026-08-18 23:21; UTC

News
Correlated Moves

Silver is trading lower in after-market hours, reflecting a decline alongside the United States Copper Index Fund. Silver remains above its 20-day moving average.

2026-08-18 23:21; UTC

Event
News

Jack Henry & Associates projects fiscal 2027 GAAP sales of $2.684 billion to $2.709 billion, exceeding analyst estimates, as shares rise in after-market hours.

2026-08-18 23:21; UTC

News

Evolution Petroleum shares are lower in after-market trading following a public offering announcement to fund a $16 million acquisition in the Midland Basin.

2026-08-18 23:21; UTC

News

Norfolk Southern completed its Living Shoreline project and advanced in after-market trading, showing strength above its 20-day moving average.

2026-08-18 23:21; UTC

News

Enovix Corporation shares rise in after-market hours as executives reassure investors and reaffirm Q3 2026 revenue guidance of $9.0 million to $10.0 million.

2026-08-18 23:11; UTC

Correlated Moves
News

Photronics Inc is facing a potential securities fraud lawsuit, contributing to a decline in after-market trading. The Russell 2000 Index also showed a slight decrease.

2026-08-18 23:06; UTC

News
Social Media

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

2026-08-18 23:02; UTC

News
Correlated Moves
Social Media

Price target raised to $1,250; shares lower in after-market.

2026-08-18 23:01; UTC

News

Toll Brothers reported third-quarter earnings of $280.1 million, exceeding expectations. Shares are trading higher in after-market hours following the results.

2026-08-18 23:01; UTC

News

Automatic Data Processing shares are lower in after-market trading despite a rebound in U.S. private-sector hiring, amid rising U.S. Treasury yields.

2026-08-18 23:01; UTC

News
Social Media

Mercury Systems shares fell after reporting a decline in net income to $798,000 and missing adjusted EPS estimates by $0.02 in after-market trading.

2026-08-18 23:01; UTC

News

Union Pacific shares are higher in after-hours trading as the Surface Transportation Board advances merger discussions with Norfolk Southern, boosting investor sentiment.

2026-08-18 23:01; UTC

News
ETF Constituents

The Vanguard Growth ETF is higher in after-market trading, supported by gains in META and AMZN, despite broader market pressures from inflation and geopolitical tensions.

2026-08-18 23:01; UTC

News
Social Media
Event

Keysight Technologies reported third-quarter revenue of $1.846 billion, exceeding expectations. Shares rose in after-market trading following the strong earnings and raised guidance.

2026-08-18 23:01; UTC

News

Blue Owl Capital shares are higher in after-market hours as Blue Owl Technology Finance prices $400 million in bonds, exceeding its $200 million target.

2026-08-18 23:01; UTC

News
Social Media

Dell Technologies shares are lower in after-market trading amid broader market pressures and rising U.S. Treasury yields ahead of its September 1 earnings call.

2026-08-18 23:01; UTC

News

Kennametal Inc appointed Dawne S. Hickton and Richard J. Harshman to its Board of Directors, prompting shares to advance in after-market trading.

2026-08-18 22:02; UTC

News

Curtiss-Wright Corp announced a $100 million expansion of its share repurchase program, raising total buybacks to $260 million for 2026. Shares are higher in after-market trading.

2026-08-18 21:03; UTC

News

Geron Corporation's shares are lower in after-market trading following the grant of stock options to new employees at an exercise price of $1.53.

2026-08-18 21:01; UTC

News

Cinemark Holdings Inc. shares rise after *Spider-Man: Brand New Day* becomes the highest-grossing domestic film in the company's history within three weeks of release.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

27.34% į viršų

12 mėnesių prognozė

Vidutinis 32.65 USD  27.34%

Aukščiausias 45 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

156 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat